Analysis of the monoclonal antibody pembrolizumab in human blood collected via volumetric adsorptive microsampling (VAMS) technology and utilizing LC-MS/MS detection

APA 2023 -- A study assessing the feasibility of performing quantitative analysis of Pembrolizumab in human whole blood collected using Mitra� (Neoteryx) volumetric adsorptive microsampling (VAMS) devices was conducted. This work builds on previous studies within our lab demonstrating the feasibility of working with this technology for small-molecule therapeutics. To support drug development, it is important to understand how analytical workflows may be deployed in support of the continued shifting of pipelines toward large molecule therapeutics. Pembrolizumab, a humanized monoclonal IgG4 antibody directed against PD-1 (commonly prescribed for the treatment of various cancer types), was selected to assess the practicality of protein analysis via LC-MS/MS analysis coupled with VAMS technology.